item management s discussion and analysis of financial condition and results of operations overview the following management s discussion and analysis of financial condition and results of operations contains forward looking statements that involve risks and uncertainties 
when used in this report  the words intend  anticipate  believe  estimate  plan and expect and similar expressions as they relate to us are included to identify forward looking statements 
repligen s actual results could differ materially from those anticipated in these forward looking statements and are a result of certain factors  including those set forth under certain factors that may affect future results and elsewhere in this report 
results of operations fiscal year ended march  compared with fiscal year ended march  revenues 
total revenues for fiscal were  as compared to  in fiscal  an increase of  or 
this increase was largely attributable to increased product sales of recombinant protein a and an increase in investment income due to higher average cash and cash equivalent and marketable securities balances 
product revenues for fiscal were  compared to  in fiscal  an increase of 
the increase in the product sales volume is attributed the initiation of product shipments to apbiotech under a supply agreement executed in may and strong demand from monoclonal antibody producers for protein a products 
sales of protein a products accounted for of our revenues in fiscal research and development revenues for fiscal include revenues relating to drug discovery collaboration arrangements with pharmaceutical partners  licensing revenue and revenue generated from phase i and phase ii government grants from the national institutes of health and the national science foundation 
the decrease in research and development revenues of  or from fiscal levels is primarily attributable to the discontinuance of research collaborations and grant programs as the company focuses its staffing on its own development programs 
investment income for fiscal was  an increase of  or from  for fiscal the increase in investment income is due to higher average cash  cash equivalent and marketable securities balances and higher interest rates 
other revenues for the fiscal period decreased by approximately  from the comparable fiscal period primarily due to gains on sales of unused equipment during fiscal year expenses 
total expenses for fiscal were  compared to  in fiscal  an increase of  or 
increased expenses in fiscal were attributable to our increased product development activities and a licensing fee of  paid to chirhoclin  inc in connection with the licensing of two secretin diagnostic products 
research and development expenses for fiscal were  compared to  in fiscal  an increase of  or 
research and development costs for fiscal include the  licensing payment to chirhoclin 
fiscal research and development costs include  in costs associated with the acquisition of rights to certain patent applications covering the use of secretin in the treatment of autism 
in addition  the increase in research and development expenses in reflects increased costs associated with our drug development programs for secretin and ctla ig 
we anticipate that research and development expenses will continue to increase significantly as we increase our investment in its drug development programs during fiscal selling  general and administrative expenses for fiscal were  compared to  in fiscal  an increase of  or 
included in selling  general and administrative expenses for fiscal were one time charges associated with a financial advisory agreement with paramount capital of  including a non cash charge of  associated with the issuance of warrants to purchase common stock 
cost of product sales for fiscal totaled  compared to  in fiscal  which represents an increase of  or over the prior fiscal year 
cost of product sales in fiscal were of product revenues versus of product revenues for fiscal the decrease in cost of revenues as a percentage of sales is due primarily to increased protein a product sales offset by expenses associated with the start up of the manufacture of protein a for amersham pharmacia biotech and the write off of certain obsolete raw materials and work in process resulting from the introduction of a new protein a product that took place during fiscal fiscal year ended march  compared with fiscal year ended march  revenues 
total revenues for fiscal were  as compared to  in fiscal  an increase of  research and development revenues for fiscal totaled  including revenues relating to drug discovery collaboration arrangements with pharmaceutical partners  licensing revenue  and revenue generated from a phase ii small business innovation research grant from the national institutes of health 
the increase in research and development revenues of  or from fiscal levels is primarily attributable to licensing payments relating to intellectual property rights licensed to neocrin  co 
during fiscal this licensing payment accounted for more than of total revenues 
research and development revenue accounted for of our total revenues 
product revenues for fiscal were  compared to  in fiscal the decrease in the product sales volume is attributed to a decrease in sales of reagent products partially offset by the increase in sales of protein a 
sales of protein a products accounted for of our revenues in fiscal investment income for fiscal was  a decrease of  from  for fiscal this decrease in investment income was due primarily to the sale of non investment securities held by repligen during fiscal offset by higher average funds available for investment during fiscal other revenues for the fiscal period decreased by approximately  from the comparable fiscal period due primarily to the one time sale of equipment and furnishings 
expenses 
during fiscal  total expenses were  significantly higher than fiscal expenses of  research and development expenses for fiscal  totaled  an increase of  or  from fiscal levels 
fiscal research and development costs include the  charge associated with the acquisition of rights to certain patent applications covering the use of secretin in the treatment of autism and expenses associated with the expansion of our clinical development activities 
cost of product sales for fiscal totaled  an increase of  from the prior fiscal year 
cost of product sales in fiscal were of product revenues versus of product revenues for fiscal this increase is largely attributable to a write off of certain obsolete raw materials and work in process resulting from the introduction of a new protein a product in fiscal selling  general and administrative expenses for fiscal were  an increase from fiscal of  this increase is partly attributable to a noncash charge associated with the issuance of warrants for legal services related to repligen s complaint filed against bristol myers squibb 
liquidity and capital resources we have financed our operations primarily through placements of equity securities and revenues derived from product sales  collaborative research agreements  government grants  and payments on licensing and royalty agreements 
total cash  cash equivalents and marketable securities increased to  at march  from  at march  the increase of  reflects proceeds from financing activities of  resulting from the sale of our common stock to certain investors through two private placements during fiscal and warrant and stock option exercise proceeds of approximately  working capital increased to  at march  from  at march  repligen s operating activities in used cash of approximately  consisting of a net loss from operations incurred during the year ended march  of approximately  an increase in accounts receivable of  offset by noncash charges for depreciation and amortization of  and warrant issuance of  and an increase in accounts payable and accrued expenses of  and  respectively 
during fiscal  we purchased  of capital equipment  consisting of laboratory and office equipment 
we expect to incur significantly higher costs in fiscal as a result of expanded research and development costs associated with the expansion of activities associated with clinical trials of our proprietary drug candidates 
in addition  under terms of our secretin diagnostic agreement with chirhoclin  if the fda approves a nda  we will be required to pay chirhoclin future milestones in cash and our common stock as well as royalties on sales 
we believe that we have sufficient resources to satisfy our working capital and capital expenditure requirements for the next twenty four months 
should we need to secure additional financing to meet its future liquidity requirements  we may not be able to secure such financing  or obtain such financing on favorable terms because of the volatile nature of the biotechnology market place 
new accounting standards in june  the fasb issued sfas no 
 accounting for derivative instruments and hedging activities 
sfas no 
establishes accounting and reporting standards for derivative instruments  including certain derivative instruments embedded in other contracts collectively referred to as derivatives and for hedging activities 
sfas no 
 as amended by sfas no 
 is effective for all fiscal quarters of fiscal years beginning after june  this new standard is not anticipated to have a significant impact on our financial statements based on its current structure and operations 
staff accounting bulletin sab no 
 revenue recognition  was issued in december sab will require companies to recognize certain upfront nonrefundable fees and milestone payments over the life of the related alliance when such fees are received in conjunction with alliances that have multiple elements 
the company is required to adopt this new accounting principle through a cumulative charge to the statement of operations  in accordance with accounting principles board opinion apb no 
 accounting changes  no later than the first quarter of fiscal we are currently evaluating the effects on sab no 
on our financial statements and based upon current guidance we do not expect it to have a significant impact on our financial statements 
year to date  we have not experienced any problems with our computer systems relating to the year issue 
we are also unaware of any material year problems with our customers or vendors 
accordingly  we do not anticipate incurring material expenses or experiencing any material operational disruptions as a result of any year problems 

